Total syntheses of alkaloid cis-223B and xenovenine are reported in 3 and 4 steps respectively using a two-directional synthesis/triple reductive amination strategy, and their neurotoxic properties assessed

Alexandre Barthelme

Arredondo

Asano

Ayer

Badio

Brior

Daly

David Richards

Garraffo

Gignoux

Ian R. Mellor

Jiang

Jones

King

Lathbury

Legeay

Liddell

Narberhaus

Newton

Prakash

Robbins

Robert A. Stockman

Schmeller

Takahata

Toyooka

Tsuneki

Tursch

Wang

Barthelme, Alexandre

Richards, David

Mellor, Ian R.

Stockman, Robert A.

Name not available

A two-directional approach to pyrrolizidines: total syntheses and biological evaluation of alkaloid cis-223B and (+/-)-xenovenine

Nottingham eTheses

Journal Name Cite this: DOI: 10.1039/c0xx00000x www.rsc.org/xxxxxx Dynamic Article Links ► ARTICLE TYPE  This journal is © The Royal Society of Chemistry [year] [journal], [year], [vol], 00–00  |  1 A Two-Directional Approach to Pyrrolizidines: Total Syntheses and Biological Evaluation of Alkaloid cis-223B and (±)-Xenovenine Alexandre Barthelme,*a David Richards,b Ian Mellorb and Robert A. Stockman*a Received (in XXX, XXX) Xth XXXXXXXXX 20XX, Accepted Xth XXXXXXXXX 20XX DOI: 10.1039/b000000x 5 Total syntheses of alkaloid cis-223B and xenovenine are reported in 3 and 4 steps respectively using a two-directional synthesis / triple reductive amination strategy, and their neurotoxic properties assessed.  Pyrrolizidine alkaloids (PAs) are widely present in nature. In plants they are produced as a defence mechanism against insect herbivores, where more than 650 PAs and PA N-oxides have 10 been isolated from 6000 different species (REF). This class of alkaloids is also present in moths, ants and poisonous frogs. The occurrence in anuran skin was first reported in 1993 for a Bufonid (Melanophryniscus) toad.1 To date, 26 3,5-PAs including stereoisomers have been assigned to the class. These compounds 15 display a broad range of biological activity, including glucosidase inhibition and anti-HIV potency, and can also play a necrotic and allergic role against living organisms, as they are used as chemical defence by batrachians.2 There are cases where the same alkaloids have been isolated in myrmicin ants, raising the 20 hypothesis that the presence of some alkaloids in frogs could be caused by their dietary source in this case, illustrated by alkaloid cis-223H.1  In order to quickly access this class of molecules, we proposed a simple bio-inspired approach through a triple reductive 25 amination. Starting from a triketone, we would form in one step 2 rings and 3 carbon-nitrogen bonds (Scheme 1). We surmised that the folded structure of the bicyclic system would enable us to attain the required stereochemistry by thermodynamic control.  30     Scheme 1. Retrosynthetic analysis 35   Although there is no direct biomimetic proof of the supposed synthetic pathway for these pyrrolizidines, we infered a similar mechanism to the one observed for alkaloid biosynthesis in ants and ladybirds.3 It has been particularly well documented in the 40 case of coccinelline and precoccinelline.4   To explore our bio-inspired triple reductive amination strategy, two natural product targets were selected: the symmetrical alkaloid cis 223B 1, and non-symmetric (±)-xenovenine 2 (Scheme 2). We surmised that adaption of our previous methods 45 in two-directional synthesis5 would be highly suited to the simple synthesis of the triketone precursors.    50      55     Figure 1. Structures of alkaloid cis-223B and xenovenine 60   Alkaloid cis 223B contains two stereogenic centres. Its central planar symmetry provides a meso configuration. 1 Was identified by GC-MS for the first time in 1989 in bufonid toads Melanophrynzscus stelzneri (Argentina) and the frog Oophaga 65 pumilio (Panama) but never was isolated.1,6 The first and only synthesis of alkaloid cis 223B was reported by our group in 2009: the latter was obtained in 7 steps and 43% overall yield.7 A synthesis of the trans configuration was later reported by Toyooka.8 (±)-Xenovenine was isolated in 1980 from the venom 70 of the ant species Solenopsis xenoveneum by Jones and co-workers.9 Structurally, this molecule is formed of a pyrrolizidine core with a 3,5-unsymmetrical substitution. Various syntheses of 2 have been published between 1986 and 2000.10 The biological properties of either compound have not been reported. 75 Results and discussion  Using a two-directional approach, our initial synthesis started with the acetal protection of diethyl 4-oxopimelate 3 to the diester 4 (Scheme 2). The latter was then converted to Weinreb diamide 5. The dialkylation of 5 with butylmagnesium bromide and 80 subsequent deprotection of the central ketone gave access to the key triketone intermediate 7a in 4 linear steps and 39% yield. The process was then later streamlined by simply allowing the deprotection to occur directly after the alkylation. A further development even allowed access to 7a directly from 4, enabling 85 in one pot: diamide formation, dialkylation and acetal deprotection in 25% overall yield. NHNHalkaloid cis 223B1(±) xenovenine2NR1 R2HOO OR2R1reductiveamination 2  |  Journal Name, [year], [vol], 00–00 This journal is © The Royal Society of Chemistry [year]   Scheme 2. Synthesis of cyclisation precursors   To convert the triketone precursors 7a and 7b to the corresponding alkaloid cis-223B and the bis C3-analogue 8, 5 several reductive amination conditions were attempted (Table 1). Conditions were optimised for the precursor 7b, with the best result obtained with 2 equivalents of sodium cyanoborohydride and 1.6 equivalents of ammonium acetate in methanol at 23 °C for 14 hours, giving a modest 29% yield of pyrrolizidine 8. These 10 same conditions gave an improved 40% yield of alkaloid cis-223B when applied to the reaction of the longer chain triketone 7a. This increase in yield is likely down to the reduced volatility of the pyrrolizidine 1 vs 8.  Scheme 3. Synthesis of xenovenine 15 Having successfully demonstrated our two-directional approach for the synthesis of alkaloid cis-223B and chain-shortened analogue 8, we next turned our attention to the the possibility of accessing non-symmetrical pyrrolizidines. Using a sequential Grignard addition strategy to symmetric protected diamide 6, 20 with addition of the longer chain first, followed by the methyl group, we were able to gain access to the non-symmetrical triketone 9. The best isolated yield obtained for 9 after optimisation was 27% (Scheme 3). Our optimised conditions for the triple reductive cyclisation was then successfully applied to 25 triketone 9, which, upon reaction gave (±)-xenovenine 2 as a single diasteroisomer in 24% yield. Jones reported a related triple reductive amination in his report of the isolation of xenovenine,11 which gave a mixture of diastereomers. We were therefore particularly pleased to find that our optimised procedure gave the 30 product as a single diastereomer. Biological evaluation  PAs are known to be toxic to humans and other mammals12 as well as insects.13 Most studies have focussed on PAs isolated from plants, and information about animal derived PAs is limited. 35 The main toxic activity of plant PAs appears to be hepatotoxicity, caused indirectly by pyrrole metabolites.11 Other alkaloids isolated from anurans are known to display neurotoxic activity by interacting directly with specific ion channels within the nervous system. One recognised target is the nicotinic acetylcholine 40 receptor.14 Binding studies have shown that twelve of thirteen plant PAs tested do not bind competitively to neuronal-nAChR,15 Table 1. Optimisation of triple reductive amination of triketones    Entry Solvent Reagents/eq Temp/ Time Product Yield (%) 1 MeOH NaBH3CN 2.0 NH4OAc 1.6 KOH 0.2 RT 14h 8 13% 2 MeOH NaBH3CN 2.0 NH4OAc 1.6 RT 14h 8 traces 3 MeOH NaBH3CN 2.0 NH4Cl 1.6 RT 14h 8 29% 4 THF NaBH(OAc)3 3.0 NH4OAc 5.0 Cat. acetic acid 60 °C 1h 8 25% 5 EtOH NH3/EtOH 5.0 Ti(OEt)4 2.5 NaBH4 1.5 RT 14h 8 7% 6 HCO2H H2NCHO 12.0 170 °C 4h 8 - 7 MeOH NaBH3CN 2.0 NH4OAc 1.6 RT 14h 1 40% 8 MeOH Et3SiH 2.0 NH4OAc 1.6 RT 14h 8 -  n = 2 7an = 3 7bOO( )nONHn = 2 8n = 3 1( )n( )n ( )nconditions69C7H15OO ONONO1) C7H15MgBr2) MeMgBrTHF-60 ˚ C  to RT3) 4N HCl27%OOOONHNH4OAcNaBH3CNMeOHRT24%(±) xenovenine2HNO1)2) RMgCl25% R = Bu28%  R = Pr3) 6M HClEtOOC COOEtOEtOOC COOEtOOHNOiPrMgClTHF-15 oC to RT77%OONONOTHF0 oC to RT14hO OROO4M Aq. HClTHF0°C to RT14h97% R=Bu98% R=PrO ORRORethylene glycolPPTS, toluenereflux 12hDean-StarkOO6a R = Bu, 52%6b R = Pr, 59%7a R = Bu7b R = Pr345HCl100%RMgCl This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |  3 but a number of PAs isolated from anuran skin display high affinity for Torpedo muscle-type nAChR.16 Spiropyrrolizidines are non-competitive antagonists of nAChR which display selectivity for neuronal over muscle-type receptors.17  Here we show inhibition of acetylcholine induced nAChR currents by cis-5 223B and (±)-xenovenine using patch-clamp of TE671 cells expressing human muscle-type nAChR.18 The results shown in Figure 1 demonstrates clear, concentration dependent inhibition of the steady state current by both cis-223B and (±)-xenovenine, with IC50 values of 120µM and 43.2µM respectively. Both 10 compounds clearly inhibit the nicotinic acetylcholine response at high concentrations but the IC50 values generated are modest when compared with other alkaloids isolated from anuran skin. Spiropyrrolizidines are known to show selectivity for neuronal over muscle-type nAChR,16 and it is possible that this is also true 15 of these compounds. Further investigation into the selectivity of these compounds for neuronal-nAChR and different sub-types thereof would reveal their potential as therapeutic leads for nAChR abberations such as slow channel myasthenic syndrome. Figure 1. Inhibition of ACh (10µM) induced currents in TE671 cells 20 expressing human muscle-type nAChR by a) cis 223B and b) (±) xenovenine at Vh -75mV. Typical traces showing ACh elicited currents (left) and when co-applied with pyrollizidines (100µM)(centre). Vertical bars represent 200pA and horizontal bars show 1s perfusion period. Concentration/inhibition plots fitted with non-linear regression curves. 25 The current at 1s after onset (the point at which antagonism is greatest) was normalised against the preceding ACh only response at the same time point. Values represent mean ± SEM for 5-12 cells. Conclusions In conclusion we have applied a bio-inspired cascade reductive 30 amination methodology to the synthesis of alkaloid cis-223B 1 (3 steps, 10% yield) and C3-analogue 8 (3 steps, 8% yield).  This method was further developed to access unsymmetrical pyrrolizidine alkaloids, demonstrated by the diastereoselective synthesis of (±)-xenovenine 2 in 4 steps and 5% overall yield. 35 Despite the relatively modest overall yields (partially due to volatility of the products), these synthetic pathways remain by far the shortest syntheses described for 1 and 2, and demonstrate the overall effectiveness of the combined two-directional synthesis / tandem reaction strategy.19 The overall strategy should be 40 applicable to a wide range of 3,5-disubstituted pyrrolizidines. Furthermore, electrophysiology assays performed on nAChR from human muscle cells enabled us to determine the IC50s of both natural products, confirming for the first time the suspected neurotoxic properties of these natural products. 45 University of Nottingham (AB), EPSRC (RAS, EP/E055346) are acknowledged for funding. Notes and references a School of Chemistry, University of Nottingham, Nottingham, NG7 2RD E-mail: Robert.stockman@nottingham.ac.uk 50 b School of Biology, University of Nottingham, Nottingham, NG7 2RD † Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/b000000x/  1. H. M. Garraffo, T. F. Spande, J. W. Daly, A. Baldessari and E. G. Gros, J. Nat. Prod., 1993, 56, 357. 2. J. R. Liddell, Nat. Prod. Rep., 1998, 15, 363-370; N. Asano, R. J. Nash, R. J. Molyneux and G. W. J. Fleet, Tetrahedron: Asymm., 2000, 11, 1645. 3. A. G. King and J. Meinwald, Chem. Rev., 1996, 96, 1105-1122. 4. B. Tursch, J. C. Braekman, D. Daloze, C. Hootele, D. Losman, R. Karlsson and J. M. Pasteels, Tetrahedron Letters, 1973, 201; B. Tursch, D. Daloze, J. C. Braekman, C. Hootele and J. M. Pasteels, Tetrahedron, 1975, 31, 1541; W. A. Ayer and L. M. Browne, Heterocycles, 1977, 7, 685. 5. S. J. Roe, J.-C. Legeay, D. Robbins, P. Aggarwal and R. A. Stockman,  Chem. Commun., 2009, 4399; A. F. Newton, S. J. Roe, J.-C. Legeay, P. Aggarwal, C. Gignoux, N. J. Birch, R. Nixon, M.-L. Alcaraz and R. A. Stockman,  Org. Biomol. Chem., 2009, 7, 2274 6. J. W. Daly, T. F. Spande and H. M. Garraffo, J. Nat. Prod., 2005, 68, 1556. 7. J. C. Legeay, W. Lewis and R. A. Stockman, Chem. Commun., 2009, 2207. 8. N. Toyooka, D. J. Zhou, H. Nemoto, Y. Tezuka, S. Kadota, N. R. Andriamaharavo, H. M. Garraffo, T. F. Spande and J. W. Daly, J. Org. Chem., 2009, 74, 6784. 9. T. H. Jones, M. S. Blum, H. M. Fales and C. R. Thompson, J. Org. Chem., 1980, 45, 4778-4780. 10. D. Lathbury and T. Gallagher, J. Chem. Soc., Chem. Commun., 1986, 1017; T. Jiang and T. Livinghouse, Org. Lett., 2010, 12, 4271; H. Takahata, H. Bandoh and T. Momose, J. Org. Chem., 1992, 57, 4401; V. M. Arredondo, S. Tian, F. E. McDonald and T. J. Marks, J. Am. Chem. Soc., 1999, 121, 3633; X. K. Liu, X. Zheng, Y. P. Ruan, J. Ma and P. Q. Huang, Org. Biomol. Chem., 2012, 10, 1275. 11. T. H. Jones, R. J. Highet, A. W. Don and M. S. Blum, J. Org. Chem., 1986, 51, 2712. 12. A. S. Prakash, T. N. Pereira, P. E. B. Reilly and A. A. Seawright, Mutation Research, 1999, 443, 53. 13. I. Narberhaus, V. Zintgraf and S. Dobler, Chemoecology, 2005, 15, 121. 14. H. Tsuneki, Y. You, N. Toyooka, S. Kagawa, S. Kobayashi, T. Sasaoka, H. Nemoto, I. Kimura and J. A. Dani, Mol. Pharmacol., 2004, 66, 1061; N. Toyooka, H. Tsuneki, S. Kobayashi, Z. Dejun, M. Kawasaki, I, Kimura, T. Sasaoka and H. Nemoto, Cur. Chem. Biol., 2007, 1, 97; X. Wang, H. Tsuneki, N. Urata, Y. Tezuka, T. Wada, T. Sasaoka, H. Sakai, R. A. Saporito and N. Toyooka, Eur. J. Org. Chem., 2012, 2012, 7082. 15. T. Schmeller, A. El-Shazly and M. Wink, J. Chem. Ecol., 1997, 23, 399. 16. H. Takahata, S. Takahashi, N. Azer, A. T. Eldefrawi and M. E. Eldefrawi, Bioorg. Med. Chem. Lett., 2000, 10, 1293. 17. B. Badio, D. Ski, Y. Shin, K. D. Hutchinson, W. L. Padgett and J. W. Daly, Biochem. Pharmacol., 1996, 52, 933. 18. T. Brior, I. R. Mellor, D. B. Tikhonov, I. Neagoe, Z. Shao, M. J. Brierley, K. Strømgaard, J. W. Jaroszewski, P. Krogsgaard-Larsen, and P. N. R. Usherwood, Mol. Pharmacol., 2003, 64, 954. 19. For other recent examples of this approach see: C. Gignoux, A. F. Newton, A. Barthelme, M-L. Alcaraz and R. A. Stockman, Org. Biomol Chem., 2012, 10, 67; D. Robbins, A. F. Newton, C. Gignoux, J.-C. Legeay, A. Sinclair, M. Rejzek, C. A. Laxon, S. K. Yalamanchili, W. Lewis, M. A. O'Connell and R. A. Stockman, Chemical Science, 2011, 2, 2232. 

Crossref

Chemical Communications

A two-directional approach to pyrrolizidines: total syntheses and biological evaluation of alkaloid cis-223B and (±)-xenovenine

Nottingham ePrints

Repository@Nottingham

http://eprints.nottingham.ac.uk/35316/1/ChemComm%202013.pdf

A two-directional approach to pyrrolizidines: total syntheses and biological evaluation of alkaloid cis-223B and (+/-)-xenovenine

Abstract

Similar works

Full text

Available Versions

Name not available

Nottingham eTheses

Name not available

Crossref

Nottingham ePrints

Repository@Nottingham